

# Experimental evolution of resistance to an antimicrobial peptide

Gabriel G. Perron<sup>1</sup>, Michael Zasloff<sup>2</sup> and Graham Bell<sup>1,\*</sup>

<sup>1</sup>Department of Biology, Mc Gill University, 1205 Ave Dr Penfield, Montreal, Que H3A 1B1, Canada

<sup>2</sup>Faculty of Research and Translational Science, Georgetown University Medical Center, Georgetown, Washington, DC 20057, USA

A novel class of antibiotics based on the antimicrobial properties of immune peptides of multicellular organisms is attracting the increasing interest as a major weapon against resistant microbes. It has been claimed that cationic antimicrobial peptides exploit fundamental features of the bacterial cell so that resistance is much less likely to evolve than in the case of conventional antibiotics. Population models of the evolutionary genetics of resistance have cast doubt on this claim. We document the experimental evolution of resistance to a cationic antimicrobial peptide through continued selection in the laboratory. In this selection experiment, 30/32 lineages of *Escherichia coli* and *Pseudomonas fluorescens* independently evolved heritable mechanisms of resistance to pexiganan, an analogue of Magainin, when propagated in medium supplemented with this antimicrobial peptide for 600–700 generations.

**Keywords:** antibiotic resistance; antimicrobial peptides; *Escherichia coli*; *Pseudomonas fluorescens*; experimental evolution; selection experiment

## 1. INTRODUCTION

The evolution of resistance to every widely used commercial antibiotic has gone a long way toward annulling recent advances in antibacterial chemotherapy. In the past 50 years, resistance to every new antibiotic has appeared in microbial populations within a few years of its introduction (Palumbi 2001). The decline in the effectiveness of current therapies has led to a search for new kinds of agent, including antibiotics based on cationic antimicrobial peptides, which are part of the innate immune system of all multicellular organisms (Hancock *et al.* 1995; Andreu & Rivas 1998; Zasloff 2002; Reddy *et al.* 2004; Toke 2005).

Cationic antimicrobial peptides are translated using the ribosomes, in the usual fashion of protein synthesis, and are, therefore, referred to as RAMPs, for ribosomally synthesized antimicrobial peptides (Hancock & Chapple 1999). The RAMPs are gene-encoded polypeptides composed of fewer than 100 amino acids (Huang 2000) and have a net positive charge conferred by lysine and arginine residues (Hancock 2001). The selective toxicity of RAMPs toward bacterial cells is primarily due to an initial electrostatic interaction between the peptide and the anionic phospholipids headgroups in the outer leaflet of the bacterial cytoplasmic membrane (Zasloff 2002; Yeaman & Yount 2003). Although RAMPs are generally thought to act by disrupting membrane integrity, their detailed modes of actions are varied and have been extensively reviewed in Yeaman & Yount (2003), Brogden (2005) and Lohner & Blondelle (2005).

Molecular mechanisms of resistance to RAMPs have been identified in several bacterial groups (Devine & Hancock 2002; Bell & Gouyon 2003; Yeaman & Yount 2003) but may be exceptional because of the fundamental

changes in membrane structure that would be needed to confer effective resistance (Zasloff 2002). Host defence peptides have remained effective against bacterial infections for at least 10<sup>8</sup> years, despite the continual presence of these peptides in bacterial environments, and we may infer that resistance is very unlikely to evolve in the short term (Zasloff 2002). The great diversity of RAMPs, the presence of several different kinds at the infection site and their different modes of action might have impeded the evolution of resistance in natural bacterial populations. Evolutionary biologists have argued, however, that the therapeutic use of particular RAMPs would alter natural environments by creating a source of specific and continued selection that might readily lead to the evolution of resistance (Bell & Gouyon 2003). This is of particular concern because of the possibility of cross-resistance to human defence peptides.

Resistance to RAMPs has been identified as a necessary component of pathogenesis in certain bacteria (Groisman *et al.* 1992; Peschel & Collins 2001; Fedtke *et al.* 2004) and constructed in the laboratory (Guo *et al.* 1998; Tamayo *et al.* 2005). There is no adequate experimental investigation, however, of the evolutionary response of populations to prolonged exposure to a therapeutic dose. Previous selection experiments (Hancock 1997; Ge *et al.* 1999b) have considered only brief episodes of a few generations of selection; resistance to conventional antibiotics may appear on this time scale, but the evolution of resistance through cumulative change involving several loci cannot be excluded.

The objective of this study was to determine whether the resistance to a RAMP would evolve under continued selection. We designed a selection protocol, where clonal lineages of *Pseudomonas fluorescens* and *Escherichia coli* were grown for several hundred generations in media containing increasing concentrations of a RAMP. Our

\* Author for correspondence (graham.bell@mcgill.ca).

experiment used isogenic lines where resistance can evolve only through the appearance, spread and accumulation of novel chromosomal mutations.

## 2. MATERIAL AND METHODS

### (a) *Organisms and establishment of populations*

We used the gram-negative bacteria *P. fluorescens* and *E. coli* to establish clonal lineages of isogenic non-mutator and mutator strains. We employed mutator genotypes because bacteria with abnormally high-mutation rates are frequently isolated from clinical infections and this may increase the rate of adaptation to antimicrobial agents (Miller *et al.* 2002; Chopra *et al.* 2003). Paul Rainey (University of Auckland) provided *P. fluorescens* non-mutator strain SBW25 (Lilley & Bailey 1997) and Craig Maclean (McGill University) constructed the otherwise isogenic mutator strain SBW25  $\Delta$ mutS (Craig Maclean, unpublished). *E. coli* non-mutator strain PS8, a clonal isolate of REL606 (Sniegowski *et al.* 1997), and mutator strain PS2350, a mutL genotype (Shaver & Sniegowski 2003), were provided by Paul D. Sniegowski (University of Pennsylvania). In both cases, a defect in the methyl-directed mismatch repair mechanism confers an elevated mutation rate by increasing the occurrence of point mutations after replication by a factor of about 100.

### (b) *Antimicrobial agent*

The selective agent we used is the cationic antimicrobial peptide pexiganan (Gly-Ile-Gly-Lys-Phe-Leu-Lys-Lys-Ala-Lys-Lys-Phe-Gly-Lys-Ala-Phe-Val-Lys-Ile-Leu-Lys-Lys-NH<sub>2</sub>) as described by Ge *et al.* (1999a). Pexiganan is an analogue of Magainin, an antimicrobial peptide isolated from *Xenopus laevis* (Zasloff 1987), that is synthetically modified to be used in clinical chemotherapy (Ge *et al.* 1999a). Stock solutions were filter-sterilized before use. Pexiganan was synthesized and purified as described (Ge *et al.* 1999a).

### (c) *Selection experiment*

We established for each species six non-mutator and six mutator lines growing in the presence of pexiganan, hereafter referred to as positive selection lines. In addition, we established in both species two non-mutator and two mutator lineages growing in an environment devoid of pexiganan for the entire duration of the experiment, here referred to as control selection lines. Cultures were grown in Mueller-Hinton Broth (MHB; BD Microbiology Systems, Cockeysville, MD) in shaking incubators at 28 °C (*P. fluorescens*) and 37 °C (*E. coli*). We transferred lines daily by inoculating 50  $\mu$ l of stationary phase culture to 5 ml MHB, to give a daily dilution of 100, or about 6–7 doublings. We preserved the ancestral clones frozen at –80 °C in 25% (v/v) glycerol. All lines were initially grown in a pristine environment free of pexiganan for 20 transfers. At transfer 21, we supplemented the medium of the positive selection lines with a non-inhibitory concentration of pexiganan (0.5  $\mu$ g ml<sup>-1</sup>) determined by Ge *et al.* (1999b). Afterwards, we doubled the concentration of pexiganan every 10 transfers, or fewer if the selection lines showed vigorous growth. Every time we increased the concentration of pexiganan, a sample of each line was inoculated to 25% (v/v) glycerol and stored at –80 °C. The experiment was conducted for 100 serial transfers, constituting 600–700 bacterial generations.

We measured the optical density (OD<sub>660</sub>) of each selection line daily from 200  $\mu$ l inocula for *E. coli* or 50  $\mu$ l aliquots

diluted in 150  $\mu$ l of MHB for *P. fluorescens* on 96 well microtitre plates using the narrow-beam Universal Microplate Reader (BioTek Instrument, Winooski, VT, USA). The scores for each well were corrected to that of a blank and were considered as a measure of growth of the bacterial population.

### (d) *In vitro susceptibility testing*

We assayed the resistance evolved by measuring the minimal inhibitory concentration (MIC) of pexiganan for each selection line, using samples of the whole population rather than isolated colonies. The method was modified from the broth macrodilution guidelines published by the National Committee for Clinical Laboratory Standards (NCCLS). We measured the growth of each selection line in a serial dilution of twelve pexiganan concentrations. For this, we prepared 5 ml dilutions of pexiganan in unsupplemented MHB and inoculated the vials with 50  $\mu$ l of stationary phase culture of each line. The growth of these cultures was then measured as previously described after incubation for 24 h. The MIC<sub>50</sub> of each culture was estimated as the lowest concentration of pexiganan that reduced growth by 50% or more.

We measured the initial MIC<sub>50</sub> values (before selection) for all 32 selection lines from cultures of transfer 20 tested on a dilution series ranging from 0 to 512  $\mu$ g of pexiganan per ml. Cultures were first reconditioned by two growth cycles in unsupplemented medium. The final MIC<sub>50</sub> values (after selection) were measured from fresh stationary phase cultures on a dilution series ranging from 0 to 1024  $\mu$ g of pexiganan per ml. Since NCCLS does not define standard breakpoints for isolates resistant to RAMPs, we identified the evolution of resistance as a significant increase of MIC<sub>50</sub> in positive selection lines compared to that of control selection lines (see Martinez & Baquero 2000).

### (e) *Stability of resistance*

To verify the heritable nature of the evolved resistance, we reconditioned all control and selection lines from frozen stocks and took each through four transfers (about 25–30 generations) in unsupplemented MHB. We then measured growth of two replicates in unsupplemented medium, and in medium containing concentrations of pexiganan near the lower and upper limits of tolerance as established in previous assays.

### (f) *Cost of resistance*

To evaluate the indirect response to selection, we estimated the limiting density, the rate of increase and the lag phase of two replicates of each line of *Pseudomonas* in unsupplemented medium and in medium containing pexiganan at the MIC.

## 3. RESULTS

### (a) *Initial levels of resistance*

The level of resistance in the ancestral clones, measured at transfer 20 before any selection, was concordant with previously published MICs of clinical isolates. We estimated MIC<sub>50</sub> for the 16 *P. fluorescens* ancestral lines to range from 2 to 8  $\mu$ g ml<sup>-1</sup> in the non-mutator strain and from 16 to 32  $\mu$ g ml<sup>-1</sup> in the mutator strain. Ge *et al.* (1999b) reported MIC values of pexiganan from 35 clinical *Pseudomonas* spp. isolates to range from 4 to 16  $\mu$ g ml<sup>-1</sup>. The 16 *E. coli* ancestral lines had MIC<sub>50</sub> between 32 and 128  $\mu$ g ml<sup>-1</sup> in non-mutator strain and between 16 and 256  $\mu$ g ml<sup>-1</sup> in mutator strain. Ge *et al.*




Figure 1. Growth of *Pseudomonas fluorescens* in relation to concentration of pexiganan. Mean ( $\pm$ s.e.) growth is measured as absorbance before selection (a) and after selection (b) and presents data from positive selection lines and control selection lines for wild-type (SBW25) and mutator (SBW25  $\Delta$ mutS) genotypes. Note that lineages were not assayed on concentrations above 512  $\mu\text{g ml}^{-1}$  before selection, since growth was totally inhibited.

(1999a) first reported *E. coli* MICs from 53 clinical isolates to range from 4  $\mu\text{g ml}^{-1}$  to values in excess of 256  $\mu\text{g ml}^{-1}$ . In a second publication, Ge *et al.* (1999b) reported MIC values from 137 *E. coli* clinical isolates to range from 2 to 64  $\mu\text{g ml}^{-1}$ .

The positive selection lines and control selection lines had statistically indistinguishable MIC<sub>50</sub> at transfer 20 in *P. fluorescens* (figure 1) non-mutator (variance-ratio test  $F=3.0$ ; degrees of freedom d.f.=1, 6;  $p>0.50$ ) and mutator strains ( $F<1$ ; d.f.=1, 6;  $p>0.5$ ) and in *E. coli* (figure 2) non-mutator ( $F=1.035$ , d.f.=1, 6,  $p>0.50$ ) and mutator strains ( $F<1$ ; d.f.=1, 6;  $p>0.50$ ).

#### (b) Resistance after selection

All *P. fluorescens* selection lines showed a highly significant increase in growth at high concentration of pexiganan relative to control selection lines (table 1). The six non-mutator positive selection lines evolved MIC<sub>50</sub> values above that of the two non-mutator control selection lines ( $F=44.0$ ; d.f.=1, 6;  $p<0.001$ ; figure 1b). The six mutator positive selection lines also evolved higher tolerance to pexiganan than the two mutator control selection lines ( $F=40.4$ ; d.f.=1, 6;  $p<0.001$ ; figure 1b). All *E. coli* selection lines also increased in MIC<sub>50</sub> values (table 1). The six non-mutator positive selection lines had higher MIC<sub>50</sub> values after selection than the control selection lines ( $F=24.4$ ; d.f.=1, 6;  $p<0.02$ ; figure 2b). Two of the non-mutator positive selection lines could not be propagated further at a pexiganan concentration of 200  $\mu\text{g ml}^{-1}$ . Although we subsequently selected the two




Figure 2. Growth of *Escherichia coli* in relation to concentration of pexiganan. Mean ( $\pm$ s.e.) growth is measured as absorbance before selection (a) and after selection (b) and presents data from positive selection lines and control selection lines for wild-type (PS8) and mutator (PS8 mutL) genotypes. Note that lineages were not assayed on concentrations above 512  $\mu\text{g ml}^{-1}$  before selection, since growth was totally inhibited.

lines for ten additional transfers at 160  $\mu\text{g ml}^{-1}$ , resistance to pexiganan never exceeded 200  $\mu\text{g ml}^{-1}$ . The MIC<sub>50</sub> of the six mutator positive selection lines were higher than the corresponding control selection lines values ( $F=16.7$ ; d.f.=1, 6;  $p<0.01$ ; figure 2b).

#### (c) Stability of resistance

After four transfers in unsupplemented medium, all selection lines of both species continued to be capable of undiminished growth at the MIC, whereas all control lines failed to grow.

#### (d) Cost of resistance

The growth properties of several strains that developed resistance to pexiganan were studied in media alone and in the presence of sublethal concentrations of pexiganan, and compared with the growth properties of control strains. The acquisition of pexiganan resistance did not appear to alter either growth rate or the maximal population density reached *in vitro*, either in the presence or absence of pexiganan. However, pexiganan resistance was associated with a longer lag phase in the absence of pexiganan, and a shorter lag phase in the presence of pexiganan, compared with the original strain (table 2).

## 4. DISCUSSION

Our results show unequivocally that high levels of heritable resistance to a cationic antimicrobial peptide evolved repeatedly in experimental lines of *P. fluorescens*

Table 1. Response to selection for resistance to pexiganan.

(Positive lines were cultured in medium supplemented with pexiganan, whereas control lines were cultured in unsupplemented medium. Minimum inhibitory concentration (MIC) was measured using serial macrodilution of pexiganan. Each determination was made on two independent replicates from each line.)

organism	lineages	selection treatments	no. of lines	MIC ranges	
				before selection	after selection
<i>Pseudomonas fluorescens</i>	SBW25	positive	6	2–8	768–1024
		control	2	4	48–96
	SBW25 $\Delta$ mutS	positive	6	16–32	1024+
		control	2	32	48–96
<i>Escherichia coli</i>	PS8	positive	4	32–128	768–1024
		control	2	64	128
	PS8 mutL	positive	6	16–256	512–1024
		control	2	32–64	48–64

Table 2. Growth of control and selection lines in unsupplemented medium (MHB) and in medium containing pexiganan at the MIC.

(Units of kinetic parameters are: limiting density  $K$ , absorbance (known to be highly correlated with cell density, data not shown); rate of increase  $V_{\max}$ , absorbance  $h^{-1}$ ; lag,  $h$ . Values given are overall means for two replicates of all lines. Significance of treatments (Selection, environment of election; Assay, environment of assay) was evaluated from a fixed-effects two-level ANOVA using the among-line variance as denominator in  $F$  for the Selection  $\times$  Assay interaction, and this interaction as denominator for the main effects, with d.f. = 1, 12 for all tests. Test-wise significance indicated by asterisk: \* $p < 0.01$ , \*\* $p < 0.001$ .)

		arithmetic means				ANOVAs ( $F$ )		
		MH broth		pexiganan		treatment	assay	sel $\times$ assay
		control	positive	control	positive			
<i>Pseudomonas</i>								
SBW25	$K$	0.618	0.787	0.036	0.34	13.4*	46.1**	<1
	$V_{\max}$	0.867	1.856	0.033	0.41	6.9	27.7**	1.4
	lag	3.6	12.1	19.4	10.4	<1	<1	68.7**
$\Delta$ mutS	$K$	0.714	0.777	0.092	0.338	7.5	57.2**	<1
	$V_{\max}$	1.033	1.911	0.267	0.444	2.3	18.1*	2.1
	lag	6.4	12.1	18.4	9.1	<1	<1	40.1**

and *E. coli*. Since both non-mutator and mutator strains evolved resistance to pexiganan, we conclude that naturally occurring mutation rates are sufficient to create selectable variation in the populations (LeClerc *et al.* 1996; Oliver *et al.* 2000). In addition, as microbial infections build up population size comparable to that within a 5 ml vial (Lorian 1996), we think that the population parameters of our experiment were reasonably realistic. Whether resistance evolves in any particular clinical situation may depend on the details of how microbes interact with RAMPs near the epithelial surface at the site of infection. Nevertheless, our results show that, as a general rule, population processes can lead to the evolution of mechanisms of resistance to RAMPs in bacterial populations through continued selection, as predicted by Bell & Gouyon (2003).

This experiment contradicts previous reports that resistance is very difficult to obtain in the laboratory (Zasloff 2002). Our experiments, however, incorporated two features lacking in previous investigations. The first was a gradual increase in the concentration of the peptide throughout the experiment. This procedure facilitates the spread of mutations with mildly beneficial effects, which can subsequently be supplemented by further mutations of similar effect, or supplanted by mutations of large effect

(see Barbosa & Levy 2000). Screens or short-term experiments at high levels of peptide are likely to be ineffective when single mutants of major effect are rare. The second was the extension of the experiment to 100 serial transfers, allowing time for resistant mutants to appear and spread. The time required for a beneficial mutation with selection coefficient  $s$  to spread from mutation-selection equilibrium at an initial frequency  $m$  to quasi-fixation in an asexual haploid population is  $-2(\ln m)/s$  (see Hartl & Clark 1997) and where adaptation requires the accumulation of several mutants of moderate effect a screen lasting a few cycles will not effectively amplify their frequency.

The readiness with which resistance to RAMPs evolves in the laboratory is clearly inconsistent with the view that it will rarely, if ever, evolve in natural communities. On the contrary, it shows that resistance can be expected to evolve rapidly whenever bacterial populations are consistently exposed to elevated levels of RAMPs. At first sight, this conclusion seems inconsistent with the observation that most populations, in fact, lack resistance and are killed by low concentrations of RAMPs. The conditions that bacteria experience in nature are quite different, however, from those that they experience in a laboratory selection experiment. In the laboratory, a lineage can be continually

Q3

513 exposed, generation after generation, to a particular stress  
514 that limits its growth. This will create intense selection that  
515 is very likely to cause specific adaptation. The same  
516 situation will often arise when chemical agents are used  
517 therapeutically in such a way as to create chronic and  
518 widespread contamination. In more natural conditions, a  
519 lineage is exposed to a kaleidoscopic array of stresses that  
520 change from generation to generation. Even a lineage that  
521 is usually associated with animals will encounter a  
522 different range of RAMPs in each host species, and,  
523 within a single species, very often a different RAMP in  
524 different host tissues. Selection will seldom act consist-  
525 ently in any given direction, and is, therefore, unlikely to  
526 cause specific adaptation. For similar reasons, bacterial  
527 populations expressed only low levels of resistance to  
528 conventional antibiotics such as penicillin and strepto-  
529 mycin when they were first used, despite having been  
530 exposed to them in the soil for millions of years. Moreover,  
531 our selection lines express a substantial cost of resistance  
532 in the form of a much longer lag phase in the absence of  
533 antibiotic.

534 The very diversity of RAMPs, indeed, suggests that  
535 they have evolved in response to pathogen coevolution.  
536 The simplest hypothesis is that each peptide is highly  
537 specific, such that the spectrum of RAMPs produced by a  
538 given species matches the spectrum of microbes that  
539 attack it, and is liable to change as this microbial  
540 community changes. Adaptation within each pathogen  
541 species provides a further agent of change, implying that  
542 each variant is effective only so long as it is rare (in the  
543 experience of the pathogen), and loses its effectiveness,  
544 through the evolution of resistance by pathogens, should it  
545 become more frequent (see Vanhoye *et al.* 2003 for a  
546 discussion of hyloid frogs). This interpretation of RAMPs  
547 as highly dynamic systems driven by continual host-  
548 pathogen coevolution is consistent with the outcome of  
549 our experiment.

550 This study suggests that, like conventional anti-  
551 infective agents, the therapeutic use of RAMPs could  
552 result in the spread of resistant organisms. These  
553 therapeutics should be carefully and appropriately regu-  
554 lated to minimize emergence of resistant organisms from  
555 treated individuals and from environments in which large  
556 amounts of an anti-infective would be distributed, such as  
557 hospitals and stockyards (see O'Brien 2002). It is not our  
558 intention to discourage or retard the development of  
559 potentially useful antimicrobial agents. What we wish to  
560 suggest is that as we develop RAMPs for use as human and  
561 veterinary anti-infectives we also seriously consider the  
562 consequences of the emergence of resistant organisms.  
563 Will organisms that emerge resistant to a synthetic RAMP  
564 such as pexiganan also exhibit resistance to endogenous,  
565 natural antimicrobial peptides? Would these resistant  
566 organisms be more pathogenic than non-resistant strains?  
567 Could resistance against a synthetic peptide evolve *in vivo*,  
568 for example, in the setting of the long-term exposure of an  
569 animal? How should these concerns be translated into  
570 practice by the governmental regulatory bodies that  
571 ultimately approve new anti-infectives? Thoughtful anal-  
572 ysis of the potential emergence of resistance against these  
573 novel anti-infective molecules before they are in wide-  
574 spread use will, in our opinion, help maximize their  
575 ultimate benefit to society.  
576

## 5. UNCITED REFERENCES

Bell, 1997. Boman, 2000. Drlica, 2003. Ganz, 2003.  
Jensen *et al.*, 2001. Levin, 2001. NCCLS, 2003. Witte,  
2000.

We are grateful to Craig MacLean and Paul D. Sniegowski for providing us with the bacterial strains. G. B. is funded by the Natural Sciences and Engineering Research Council of Canada.

## REFERENCES

- Andreu, D. J. & Rivas, L. 1998 Animal antimicrobial peptides: an overview. *Biopolymer* **47**, 415–433. (doi:10.1002/(SICI)1097-0282(1998)47:6<415::AID-BIP2>3.0.CO;2-D.)
- Barbosa, T. M. & Levy, S. B. 2000 The impact of antibiotic use on resistance development and persistence. *Drug Resist. Update*. **3**, 303–311. (doi:10.1054/drup.2000.0167.)
- Bell, G. 1997 *The basics of selection*. New York: Chapman & Hall.
- Bell, G. & Gouyon, P. H. 2003 Arming the enemy: the evolution of resistance to self-proteins. *Microbiology* **149**, 1367–1375. (doi:10.1099/mic.0.C0122-0.)
- Boman, H. G. 2000 Innate immunity and the normal microflora. *Immunol. Rev.* **173**, 5–6. (doi:10.1034/j.1600-065X.2000.917301.x.)
- Brogden, K. A. 2005 Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?. *Nat. Rev. Microbiol.* **3**, 238–250. (doi:10.1038/nrmicro1098.)
- Chopra, I., O'Neill, A. J. & Miller, K. 2003 The role of mutators in the emergence of antibiotic-resistant bacteria. *Drug Resist. Update*. **6**, 137–145. (doi:10.1016/S1368-7646(03)00041-4.)
- Devine, D. A. & Hancock, R. E. W. 2002 Cationic peptides: distribution and mechanisms of resistance. *Curr. Pharm. Design* **8**, 703–714. (doi:10.2174/1381612023395501.)
- Drlica, K. 2003 The mutant selection window and antimicrobial resistance. *J. Antimicrob. Chemother.* **52**, 11–17. (doi:10.1093/jac/dkg269.)
- Fedtke, I., Gotz, F. & Peschel, A. 2004 Bacterial evasion of innate host defenses—the *Staphylococcus aureus* lesson. *Int. J. Med. Microbiol.* **294**, 189–194. (doi:10.1016/j.ijmm.2004.06.016.)
- Ganz, T. 2003 Defensins: antimicrobial peptides of innate immunity. *Nat. Rev. Immunol.* **3**, 710–720. (doi:10.1038/nri1180.)
- Ge, Y., MacDonald, D. L., Holroyd, K. J., Thornsberry, C., Wexler, H. & Zasloff, M. 1999a *In vitro* antibacterial properties of pexiganan, an analog of magainin. *Antimicrob. Agents Chemother.* **43**, 782–788.
- Ge, Y., MacDonald, D., Henry, M. H., Hait, H. I., Nelson, K. A., Lipsky, B. A., Zasloff, M. & Holroyd, K. J. 1999b *In vitro* susceptibility to pexiganan of bacteria isolated from infected diabetic foot ulcer. *Diagn. Microbiol. Infect. Dis.* **35**, 45–53. (doi:10.1016/S0732(99)00053-X.)
- Groisman, E. A., Parra-Lopez, C., Salcedo, M., Lipps, C. J. & Heffron, F. 1992 Resistance to host peptides is necessary for *Salmonella virulence*. *Proc. Natl Acad. Sci. USA* **89**, 11 939–11 943.
- Guo, L., Lim, K. B., Poduje, C. M., Daniel, M., Gunn, J. S., Haclett, M. & Miller, S. I. 1998 Lipid A acetylation and bacterial resistance against vertebrate antimicrobial peptides. *Cell* **95**, 189–198. (doi:10.1016/S0092-8674(00)81750-X.)
- Hancock, R. E. M. 1997 Peptides antibiotics. *Lancet* **349**, 418–442. (doi:10.1016/S0140-6736(97)80051-7.)

- Hancock, R. E. M. 2001 Cationic peptides: effectors in innate immunity and novel antimicrobials. *Lancet Infect. Dis.* **1**, 156–164. (doi:10.1016/S1473-3099(01)00092-5.)
- Hancock, R. E. M. & Chapple, D. S. 1999 Peptide antibiotics. *Antimicrob. Agents Chemother.* **43**, 1317–1323.
- Hancock, R. E. W., Falla, T. & Brown, M. M. 1995 Cationic bactericidal peptides. *Adv. Microb. Physiol.* **13**, 135–175.
- Hartl, D. L. & Clark, A. G. 1997 *Principles of population genetics*. New York: Sinauer.
- Huang, H. W. 2000 Action of antimicrobial peptides: two-state model. *Biochemistry* **39**, 8347–8352. (doi:10.1021/bi0009461.)
- Jensen, L. B., Baloda, S., Boye, M. & Aarestrup, F. M. 2001 Antimicrobial resistance among *Pseudomonas* spp. and the *Bacillus cereus* group isolated from Danish agricultural soil. *Environ. Int.* **26**, 581–587. (doi:10.1016/S0160-4120(01)00045-9.)
- LeClerc, J. E., Li, B., Payne, W. L. & Cebula, T. A. 1996 High mutation frequencies among *Escherichia coli* and *Salmonella* pathogens. *Science* **274**, 1208–1211. (doi:10.1126/science.274.5290.1208.)
- Levin, B. R. 2001 Minimizing potential resistance: a population dynamics view. *Clin. Infect. Dis.* **33**(Suppl. 3), S161–S169. (doi:10.1086/321843.)
- Lilley, A. K. & Bailey, M. J. 1997 The acquisition of indigenous plasmids by a genetically marked pseudomonad population colonising the phytosphere of sugar beet is related to local environmental conditions. *Appl. Environ. Microbiol.* **63**, 1577–1583.
- Lorian, V. 1996 *Antibiotics in laboratory medicine*. Baltimore, MD: Williams & Wilkins laboratory.
- Lohner, K. & Blondelle, S. E. 2005 Molecular mechanisms of membrane perturbation by antimicrobial peptides and the use of biophysical studies in the design of novel peptide antibiotics. *Comb. Chem. High Throughput Screen.* **8**, 241–256. (doi:10.2174/1386207053764576.)
- Martinez, J. L. & Baquero, F. 2000 Mutation frequencies and antibiotics resistance. *Antimicrob. Agents Chemother.* **33**, 1771–1777. (doi:10.1128/AAC.44.7.1771-1777.2000.)
- Miller, K., O'Neill, A. J. & Chopra, I. 2002 Response of *Escherichia coli* hypermutators to selection pressure with antimicrobial agents from different classes. *J. Antimicrob. Chem.* **49**, 925–934. (doi:10.1093/jac/dkf044.)
- NCCLS, 2003 *Approved Standards (M7-A4): methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically*, 6th edn. Villanova, PA.
- O'Brien, T. F. 2002 Emergence, spread, and environmental effect of antimicrobial resistance: how use of an antimicrobial anywhere can increase resistance to any antimicrobial anywhere else. *Clin. Infect. Dis.* **34**(3), S78–S84. (doi:10.1086/340244.)
- Oliver, A., Canton, R., Campo, P., Baquero, F. & Blazquez, J. 2000 High frequency of hypermutable *Pseudomonas aeruginosa* in cystic fibrosis lung infection. *Science* **288**, 1251–1254. (doi:10.1126/science.288.5469.1251.)
- Palumbi, S. R. 2001 Humans as the World's greatest evolutionary force. *Science* **293**, 1786–1790. (doi:10.1126/science.293.5536.1786.)
- Peschel, A. & Collins, L. V. 2001 Staphylococcal resistance to antimicrobial peptides of mammalian and bacterial origin. *Peptides* **22**, 1651–1659. (doi:10.1016/S0196-9781(01)00500-9.)
- Reddy, K. V. R., Yedery, R. D. & Aranha, C. 2004 Antimicrobial peptides: premises and promises. *Int. J. Antimicrob. Agents* **24**, 536–547. (doi:10.1016/j.ijantimicag.2004.09.005.)
- Shaver, A. C. & Sniegowski, P. D. 2003 Spontaneously arising mutL mutators in evolving *Escherichia coli* populations are the results of changes in repeat length. *J. Bacteriol.* **185**, 6076–6082. (doi:10.1128/JB.185.20.6076-6082.2003.)
- Sniegowski, P. D., Gerrish, P. J. & Lenski, R. E. 1997 Evolution of high mutation rates in experimental populations of *E. coli*. *Nature* **387**, 703–705. (doi:10.1038/42701.)
- Tamayo, R., Choudhury, B., Septer, A., Merighi, M., Carlson, R. & Gunn, J. S. 2005 Identification of *cptA*, a PmrA-regulated locus required for phosphoethanolamine modification of the salmonella enterica serovar typhimurium lipopolysaccharide core. *J. Bacteriol.* **187**, 3391–3399. (doi:10.1128/JB.187.10.3391-3399.2005.)
- Toke, O. 2005 Antimicrobial peptides: new candidates in the fight against bacterial infections. *Biopolymers* May 4.
- Vanhoye, D., Bruston, F., Nicolas, P. & Amichem, M. 2003 Antimicrobial peptides from hylid and ranin frogs originated from a 150-million-year-old ancestral precursor with a conserved signal peptide but a hypermutable antimicrobial domain. *Eur. J. Biochem.* **270**, 2068–2081. (doi:10.1046/j.1432-1033.2003.03584.x.)
- Witte, W. 2000 Ecological impact of antibiotic use in animals on different complex microflora: environment. *Int. J. Antimicrob. Agents* **14**, 321–325. (doi:10.1016/S0924-8579(00)00144-8.)
- Yeaman, M. R. & Yount, N. Y. 2003 Mechanisms of antimicrobial peptides action and resistance. *Pharmacol. Rev.* **55**, 27–55. (doi:10.1124/pr.55.1.2.)
- Zaslloff, M. 1987 Magainins, a class of antimicrobial peptides from *Xenopus* skin: isolation, characterization of two active, and partial cDNA sequence or a precursor. *Proc. Natl Acad. Sci. USA* **84**, 5449–5453.
- Zaslloff, M. 2002 Antimicrobial peptides of multicellular organisms. *Nature* **415**, 389–395. (doi:10.1038/415389a.)

769 **Author Queries**770 *JOB NUMBER:* 20053301771 *JOURNAL:* RSPB

772

773

774 Q1 Please check the inserted short title.

775 Q2 Please note that as per the style only a maximum of six  
776 keywords are allowed and hence 'pexiganan' has been  
777 deleted from the keyword list.778 Q3 Please note that the following references Bell (1997),  
779 Boman (2000), Drlca (2003), Ganz (2003), Jensen et  
780 al. (2001), Levin (2001), NCCLS (2003) and Witte  
781 (2000) are given in list but not cited in text.782 Q4 Please include all publication details in Bell (1997).  
783 Article/series title; volume/edition number(s); editor(s)  
784 names and page numbers.785 Q5 Please include all publication details in Hartl & Clark  
786 (1997). Article/series title; volume/edition number(s);  
787 editor(s) names; page numbers.788 Q6 Please include all publication details in NCCLS (2003).  
789 Article/series title; volume/edition number(s); editor(s)  
790 names; page numbers.791 Q7 Please include all publication details in Toke (2005).  
792 Volume number and page numbers.

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896